×
About 143 results

ALLMedicine™ Benign Essential Blepharospasm Center

Research & Reviews  46 results

Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a inj...
https://doi.org/10.1007/s10792-022-02253-1 10.1097/00002341-199809000-00002 10.1016/j.jns.2015.06.032 10.1016/0039-6257(91)90207-V 10.1111/aos.12002 10.1016/j.ajo.2013.11.014 10.1016/j.jtos.2017.05.008 10.1001/jamaophthalmol.2013.6243 10.1016/j.ophtha.2018.03.013 10.1097/ICO.0000000000000482 10.1167/iovs.06-1507 10.1016/j.preteyeres.2018.04.002 10.1167/iovs.08-2704 10.1097/ICO.0b013e3182261577 10.3390/medicina57030247 10.3346/jkms.2006.21.1.131 10.1167/iovs.17-23500 10.1007/s10384-016-0469-6 10.1590/S0004-27492011000600006 10.1016/j.ophtha.2012.03.004 10.1016/S0161-6420(87)33337-8 10.1007/PL00007813 10.1001/archneur.59.3.418 10.5301/ejo.5000482 10.1136/bjo.87.1.54 10.1038/eye.2015.18 10.1038/s41598-018-26750-5 10.1016/j.jtos.2017.03.006 10.1167/iovs.05-1654 10.3928/1542-8877-20060301-06 10.4274/tjo.43.48303 10.1016/S0161-6420(97)30125-0 10.1097/SCS.0000000000002435 10.1097/01.iop.0000231774.70194.3f 10.1097/ICO.0000000000000688 10.1167/iovs.10-7093 10.1136/bjo.76.3.157 10.1016/S0002-9394(02)01430-7 10.1167/iovs.03-0839 10.1016/j.ophtha.2003.06.027 10.3928/1081-597X-20040501-08 10.2147/OPTH.S305817 10.1111/ceo.12165 10.4103/ijo.IJO_41_19
International Ophthalmology; Bayraktar Bilen N, Bilen Ş et. al.

Apr 1st, 2022 - To investigate the effect of botulinum neurotoxin-A (BTX-A) treatment on dry eye symptoms, tear meniscus, corneal topography and corneal aberrometry in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS). This prospective...

Application of colored filters in patients post-traumatic brain injury: A review.
https://doi.org/10.3233/NRE-228015
NeuroRehabilitation Bansal S, Green K

Mar 29th, 2022 - Tinted lenses have been used to manage visual discomfort and photosensitivity in patients with migraines, benign essential blepharospasm (BEB) and epilepsy. The purpose of this review is to examine the existing clinical research regarding the use ...

Long-term stable efficacy of botulinum toxin A in facial movement disorders with no nee...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238266
Medicine Badarny S, Ibrahim R et. al.

Jun 24th, 2021 - Botulinum toxin A is considered an effective treatment for involuntary facial movements. We examined whether treatment efficacy maintained or changed over time with two products, Botox and Dysport, in patients with hemifacial spasm, facial synkine...

Complications of Preseptal Versus Pretarsal Botulinum Toxin Injection in Benign Essenti...
https://doi.org/10.1016/j.ajo.2021.04.029
American Journal of Ophthalmology; Sanguandikul L, Apinyawasisuk S et. al.

May 10th, 2021 - The purpose of this study was to compare ocular complications and efficacy of preseptal (PST) versus those of pretarsal (PTS) botulinum toxin type A (BoNT-A) therapy in cases of benign essential blepharospasm (BEB). Randomized clinical trial. Sett...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  2 results

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
https://clinicaltrials.gov/ct2/show/NCT00234507

Jul 29th, 2019 - The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.

rTMS and Botulinum Toxin in Benign Essential Blepharospasm
https://clinicaltrials.gov/ct2/show/NCT02370875

Dec 13th, 2017 - A two week course of rTMS therapy to achieve sustained benefits will be employed. With standard BoNT treatment, the peak-dose benefits are seen at about 4-6 weeks after the administration of injections. rTMS will be introduced during this peak-dos...

see more →

News  6 results

Cannabis Explored as Blepharospasm Treatment
https://www.medscape.com/viewarticle/962762

Nov 11th, 2021 - Cannabis oil may reduce the duration and frequency of spasms caused by benign essential blepharospasm (eye twitching), researchers say. The treatment could serve as a second-line treatment for patients who have already received botulinum toxin inj...

FDA OKs IncobotulinumtoxinA (Xeomin) First-Line in Blepharospasm
https://www.medscape.com/viewarticle/912928

May 13th, 2019 - PHILADELPHIA — The US Food and Drug Administration (FDA) has approved broadening the indication for incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) as first-line therapy for blepharospasm in adult patients, the manufacturer has announced. Benig...

Botulinum Toxin Effective for Blepharospasm in Toxin-Naïve Patients
https://www.medscape.com/viewarticle/912886

May 10th, 2019 - PHILADELPHIA — IncobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) conveys long-term safety and efficacy in patients with benign essential blepharospasm (BEB) who are botulinum toxin-naïve, new research suggests. BEB is a focal dystonia that causes...

As-Needed Jabs With New Drug for Blepharospasm Are Safe
https://www.staging.medscape.com/viewarticle/752573

Oct 31st, 2011 - October 31, 2011 (Orlando, Florida) — A new study shows that shorter injection intervals with incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals), given on an as-needed basis, are safe and effective. The study provides much-needed proof that it is ...

As-Needed Jabs With New Drug for Blepharospasm Are Safe
https://www.medscape.com/viewarticle/752573

Oct 31st, 2011 - October 31, 2011 (Orlando, Florida) — A new study shows that shorter injection intervals with incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals), given on an as-needed basis, are safe and effective. The study provides much-needed proof that it is ...

see more →

Patient Education  1 results see all →